SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is trending as rumors of potential acquisition swirl, with the community buzzing about a potential buyout after reports of a failed financing attempt from a smaller company.  Enthusiasm is building for the upcoming earnings report and the potential for a positive outcome, while some investors express skepticism toward management. Bullish sentiment is further fueled by high short interest, leading to speculation about a possible short squeeze.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

NewcelX Ltd.

NCEL is trending as investors grapple with the implications of its recent merger and reverse stock split, with some expressing confusion and concern over trading discrepancies and stock valuations. Community discussions revolve around the potential for a short squeeze and the company's future prospects post-merger. The merger with Kadimastem is seen by some as a positive catalyst, while others remain skeptical about the combined entity's valuation and potential.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals ($BCRX) is trending as investors anticipate upcoming earnings and key updates on its pipeline, including BCX17725 for Netherton syndrome. Community discussions focus on the potential for a positive conference call with improved guidance, overshadowing concerns about debt and valuation. Optimism surrounds the integration of Astria's assets and potential label expansion for Orladeyo, as analysts project earnings growth.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors discuss its high valuation and potential ahead of earnings, with some pointing to strong AI growth and government contracts as reasons for optimism. The community is debating whether the stock can maintain its momentum and if it will beat expectations. Discussions include potential stock splits and comparisons to other high-growth tech companies.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

GILD is trending due to recent earnings and analyst upgrades, though the stock's reaction is mixed, with some questioning if investor expectations weren't fully met. Community discussions revolve around the company's HIV and oncology pipeline, potential acquisitions (such as RCUS or XLO), and the impact of regulatory decisions. Several actionable alerts and technical analyses are being shared, with call options being a popular strategy.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is trending amid speculation around winter weather and potential supply constraints, with some traders anticipating a significant rally. Community discussions revolve around technical indicators, potential breakout levels, and the impact of data center energy consumption on natural gas demand. Despite strong storage levels, expectations of increased demand and potential disruptions are fueling bullish sentiment.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X Shares

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending due to LiquidTheta's LEAPS options alerts, sparking community interest in potential ROI. Additionally, news of China and Canada expanding trade and energy ties could provide tailwinds. However, concerns about consumer recession, layoffs, and banking stress are also circulating, adding complexity to the discussion around JNUG and junior gold miners.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending as the community discusses its potential for a turnaround, fueled by recent analyst upgrades and speculation around new AI-integrated products. Community members are debating whether the stock is poised for a Carvana-like surge, while others caution about the impact of the broader economic environment and short interest.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending as traders discuss its potential for a short squeeze amid high short interest and anticipation of upcoming earnings. Community members are also focused on the company's raised FY25 EBITDA guidance and positive outlook, along with potential analyst upgrades. The stock's low PE ratio and potential for international contract growth are adding to the bullish sentiment.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards amid concerns about consumer spending and lowered sales outlook, sparking debates about its affordability and competition with other fast-casual restaurants like Cava. The community is discussing potential bottom levels, possible management changes, and whether the dip presents a buying opportunity or a sign of deeper issues. Discussions also focus on portion sizes, service quality, and comparisons to alternative dining options.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FICO Grows Through Expanding Portfolio and Strong Partnerships

Fair Issac drives growth with new GenAI models, global partnerships and its AI-powered platform, reinforcing leadership in financial services.


Here's Why Momentum in Fujitsu (FJTSY) Should Keep going

Fujitsu (FJTSY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Fujitsu (FJTSY) Upgraded to Buy: Here's Why

Fujitsu (FJTSY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

 Unisys Banks on License & Support Strength: Will the Momentum Hold? 

Best Momentum Stocks to Buy for June 17th

Here's What Could Help Fujitsu (FJTSY) Maintain Its Recent Price Strength

Fujitsu (FJTSY) is on the Move, Here's Why the Trend Could be Sustainable 

Is CyberAgent (CYGIY) Stock Outpacing Its Computer and Technology Peers This Year?

Fujitsu Ltd. engages in the provision of information technology (IT) services. It operates through the following segments: Technology Solutions, Ubiquitous Solutions, and Device Solutions. The Technology Solutions segment provides system integration, consulting, outsourcing, cloud, network, and system support services. It also offers system and network products such as servers, storage systems, software, network management systems, and mobile base stations. The Ubiquitous Solutions segment covers personal computers (PCs). The Device Solutions segment includes electronic components such as semiconductor packages and batteries. The company was founded on June 20, 1935 and is headquartered in Kawasaki, Japan.

Fujitsu Limited - ADR

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.28	--	--	N/A
Q2 '25	$0.24	$0.33	35.16%	BEAT
Q1 '25	$0.14	$0.64	362.88%	BEAT
Q4 '24	$0.39	$0.43	12.52%	BEAT
Q3 '24	$0.17	$0.25	44.72%	BEAT

FJTSY
Fujitsu

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest FJTSY News

FJTSYFujitsu